GlassScriptPhysician profile
Alan P Glombicki
NPI 1669467395
$93,174.24
in general payments reported to CMS, 2019-2025
30 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Obesity Medicine (Internal Medicine) provider received nationally (typical 2025 total: $202).
See the full distribution for Obesity Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $15K · 2021: $10K · 2022: $13K · 2023: $11K · 2024: $12K · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $3,091 · Food and Beverage: $2,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,300.00 |
| Travel and Lodging | $3,090.74 |
| Food and Beverage | $2,475.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $80,713.73 | 2019-2024 | Epclusa, Vemlidy |
| Abbvie INC. | $2,628.75 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $2,470.53 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,935.20 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,284.52 | 2021-2024 | Zeposia |
| Intra-Sana Laboratories | $778.64 | 2021 | |
| Janssen Biotech, INC. | $731.41 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $503.22 | 2019-2022 | |
| Celgene Corporation | $366.33 | 2021-2023 | Zeposia |
| Shionogi INC | $200.72 | 2019 | |
| Merck Sharp & Dohme LLC | $194.98 | 2019-2023 | Vaxelis, Vaqta, Gardasil 9 |
| Medtronic, INC. | $173.29 | 2024 | Bravo |
| Dova Pharmaceuticals | $153.84 | 2019 | |
| Madrigal Pharmaceuticals | $147.49 | 2025 | Rezdiffra |
| Pfizer INC. | $147.12 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $135.18 | 2025 | Vegzelma |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Ethicon US, LLC | $104.95 | 2019 | |
| Medtronic USA, INC. | $91.45 | 2020 | |
| Redhill Biopharma INC. | $86.60 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $40.44 | 2020-2021 | |
| Braintree Laboratories, INC. | $33.57 | 2022 | |
| Mirum Pharmaceuticals, INC. | $32.00 | 2025 | Livmarli |
| Ipsen Biopharmaceuticals, INC | $27.98 | 2025 | Iqirvo |
| Allergan, INC. | $27.24 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $20.41 | 2022 | |
| Evoke Pharma, INC. | $19.65 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Glombicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.